CorFlow Therapeutics AG, a Baar, Switzerland-based completed the CHF 2.6M first close of its seed+ financing round.
The round was led by private medical device investors including Dr. Jean-Claude Laborde, who were joined by medical device entrepreneurs Jacques Séguin and Arshad Quadri.
Led by Jon H. Hoem, CEO and Co-Founder, CorFlow is developing proprietary technologies for diagnosis and treatment of microvascular obstructions (MVO). The company’s technologies aim to enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complication rates in these patients.
CorFlow, which which has raised more than CHF5M in seed funding to date, intends to use the funds to finance the 80 patients First-in-Man MOCA ((MVO with CoFI™ System Assessment) clinical trial in Europe.
The MOCA trial will investigate the diagnosis of microvascular obstruction (MVO) in up to 40 acute coronary patients and the potential therapy for these patients comparing the outcomes to current standard of care.
The Seed+ round will be the basis for raising the larger A round securing the long-term R&D, clinical and regulatory activities of the company.